Multiplex PCR
Automated targeted PCR
Manual targeted PCR
RNA extraction
Additional COVID-19 resources
QIAGEN solutions
-
QIAstat-Dx
The next generation of syndromic insights
Harness the full potential of multiplex syndromic testing and confidently provide clinical insights to patients with the highest level of versatility.
-
QIAGEN Digital Insights
Bioinformatics analysis of SARS-CoV-2 with QIAGEN Digital Insights
To support the efforts of labs sequencing the SARS-CoV-2 virus on the front lines of the COVID-19 pandemic, QIAGEN is offering free temporary licenses to researchers worldwide involved with COVID-19 research and response.
-
QIAcube Connect
Redefining automated sample processing
Fully automate QIAGEN gold-standard spin-column purification procedures with the new QIAcube Connect instrument.
-
EZ1 DSP Virus Kit
Contains all required reagents for automated purification
The EZ1 DSP Virus Kit is ideal for automated, simultaneous purification of viral nucleic acids and bacterial DNA from 1–6 or 1–14 human biological specimens.
-
QIAamp Viral RNA Mini Kit
For isolation of viral RNA from cell-free body fluids
By binding viral RNA to the QIAamp silica membrane, the QIAamp Viral RNA Mini Kit simplifies purification of viral RNA from cell-free body fluids with fast spin-column or vacuum procedures. The procedure can be fully automated.
-
EZ1 Advanced XL
For automated nucleic acid purification
With EZ1 Advanced XL you can fully automate your nucleic acid purification from a wide range of sample types relevant for molecular diagnostics.
*Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.
- Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
- This test has not been FDA cleared or approved;
- This test has been authorized by FDA under an EUA for use by authorized laboratories;
- This test has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
The NeuMoDx SARS-CoV-2 Assay is authorized under Emergency Use Authorization in the United States.
- This test has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
- This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
- The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
The NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay is authorized under Emergency Use Authorization in the United States.
- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
- This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, influenza B virus, and/or Respiratory Syncytial Virus, not for any other viruses or pathogens; and
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
The artus SARS-CoV-2 Prep&Amp UM Kit has been validated but is pending Emergency Use Authorization by the FDA.